<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01733368</url>
  </required_header>
  <id_info>
    <org_study_id>CR-1 2-015-SP-HF</org_study_id>
    <nct_id>NCT01733368</nct_id>
  </id_info>
  <brief_title>QUARTO-II Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead</brief_title>
  <acronym>QUARTO-II</acronym>
  <official_title>Observational Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimization and evolution of the patient will be evaluated over 6 months after the implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient will be enrolled into the study after Informed Consent signature and
      CRT-D+quadripolar (QuartetTM) LV lead.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Responder Patients (Structural Remodelling)</measure>
    <time_frame>6 months after implant</time_frame>
    <description>Structural remodelling is defined as a reduction &gt;15% in Left Ventricle End Systolic Volume (LVESV), measured 6 months after implant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Outcomes in CRT Responders and Non-Responders</measure>
    <time_frame>6 months after implant</time_frame>
    <description>Mortality rate,
Rate of cardiovascular hospitalizations and for any cause or
Combined endpoint (death and all-cause hospitalization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Responder Patients With Non-conventional Left Ventricular Pacing Vector</measure>
    <time_frame>6 months after implant</time_frame>
    <description>Response is defined as a reduction &gt;15% in LVESV, measured 6 months after implant.
Non-conventional pacing vectors are the pacing vectors exclusive to the Quartet LV quadripolar lead, not available in the conventional bipolar leads.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responder Patients With Conventional Left Ventricular Pacing Vector</measure>
    <time_frame>6 months after implant</time_frame>
    <description>Response is defined as a reduction &gt;15% in LVESV, measured 6 months after implant.
Conventional pacing vectors are the pacing vectors available both in the Quartet LV quadripolar lead and in the conventional bipolar leads.</description>
  </secondary_outcome>
  <enrollment type="Actual">198</enrollment>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Heart failure patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with implanted CRT-D device and a QuartetTM quadripolar lead by St. Jude
             Medical in the left ventricle.

          -  Patient with an echocardiographic study performed during 1 month prior to the implant
             and in whom End Systolic Volume of the Left Ventricle (LVESV) has been measured

          -  Patients who have granted their informed consent.

          -  Patients above 18 years.

        Exclusion Criteria:

          -  Patients that have been previously resynchronized.

          -  Patients with aortic stenosis or aortic valve prosthesis

          -  Patients who are or may potentially be pregnant.

          -  Patients with a life expectancy &lt;12 months.

          -  Patients who cannot attend the monitoring visits established by the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Alzueta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Virgen de la Victoria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>November 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2012</study_first_posted>
  <results_first_submitted>May 31, 2017</results_first_submitted>
  <results_first_submitted_qc>February 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2018</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRT</keyword>
  <keyword>Optimization</keyword>
  <keyword>Responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quadripolar Left Ventricular Lead (Quartet Lead)</title>
          <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quadripolar Left Ventricular Lead (Quartet Lead)</title>
          <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.01" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Classification</title>
          <description>The NYHA Functional Classification provides a simple way of classifying the extent of heart failure:
I Cardiac disease, but no symptoms and no limitation in ordinary physical activity.
II Mild symptoms and slight limitation during ordinary activity. III Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest.
IV Severe limitations. Experiences symptoms even while at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular Etiology: Ischemic, Non-ischemic</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Ischemic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-ischemic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QRS Duration</title>
          <units>miliseconds (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168" spread="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QRS Morphology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Left Bundle Branch Block (LBBB)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Right Bundle Branch Block (RBBB)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Interventricular Conduction Delay (IVCD)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ejection Fraction (EF)</title>
          <units>percentage (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.87" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular End Systolic Volume (LVESV)</title>
          <units>milliliters (ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155.17" spread="75.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Responder Patients (Structural Remodelling)</title>
        <description>Structural remodelling is defined as a reduction &gt;15% in Left Ventricle End Systolic Volume (LVESV), measured 6 months after implant.</description>
        <time_frame>6 months after implant</time_frame>
        <population>Patients with the 6-month follow-up completed and echocardiographic measurements available</population>
        <group_list>
          <group group_id="O1">
            <title>Quadripolar Left Ventricular Lead (Quartet Lead)</title>
            <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responder Patients (Structural Remodelling)</title>
          <description>Structural remodelling is defined as a reduction &gt;15% in Left Ventricle End Systolic Volume (LVESV), measured 6 months after implant.</description>
          <population>Patients with the 6-month follow-up completed and echocardiographic measurements available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Outcomes in CRT Responders and Non-Responders</title>
        <description>Mortality rate,
Rate of cardiovascular hospitalizations and for any cause or
Combined endpoint (death and all-cause hospitalization)</description>
        <time_frame>6 months after implant</time_frame>
        <population>Patients experiencing clinical safety event prior to the 6-month follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>6-Month CRT Responder</title>
            <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead and classified as a responder at 6 months of follow-up.</description>
          </group>
          <group group_id="O2">
            <title>6-Month CRT Non-Responder</title>
            <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead and classified as a non-responder at 6 months of follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcomes in CRT Responders and Non-Responders</title>
          <description>Mortality rate,
Rate of cardiovascular hospitalizations and for any cause or
Combined endpoint (death and all-cause hospitalization)</description>
          <population>Patients experiencing clinical safety event prior to the 6-month follow-up visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-cause hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths &amp; Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responder Patients With Non-conventional Left Ventricular Pacing Vector</title>
        <description>Response is defined as a reduction &gt;15% in LVESV, measured 6 months after implant.
Non-conventional pacing vectors are the pacing vectors exclusive to the Quartet LV quadripolar lead, not available in the conventional bipolar leads.</description>
        <time_frame>6 months after implant</time_frame>
        <population>Patients with the 6-month follow-up completed, echocardiographic measurements available and programmed with non-conventional LV pacing vector</population>
        <group_list>
          <group group_id="O1">
            <title>Quadripolar Left Ventricular Lead (Quartet Lead)</title>
            <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responder Patients With Non-conventional Left Ventricular Pacing Vector</title>
          <description>Response is defined as a reduction &gt;15% in LVESV, measured 6 months after implant.
Non-conventional pacing vectors are the pacing vectors exclusive to the Quartet LV quadripolar lead, not available in the conventional bipolar leads.</description>
          <population>Patients with the 6-month follow-up completed, echocardiographic measurements available and programmed with non-conventional LV pacing vector</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responder Patients With Conventional Left Ventricular Pacing Vector</title>
        <description>Response is defined as a reduction &gt;15% in LVESV, measured 6 months after implant.
Conventional pacing vectors are the pacing vectors available both in the Quartet LV quadripolar lead and in the conventional bipolar leads.</description>
        <time_frame>6 months after implant</time_frame>
        <population>Patients with the 6-month follow-up completed, echocardiographic measurements available and programmed with a conventional pacing vector</population>
        <group_list>
          <group group_id="O1">
            <title>Quadripolar Left Ventricular Lead (Quartet Lead)</title>
            <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responder Patients With Conventional Left Ventricular Pacing Vector</title>
          <description>Response is defined as a reduction &gt;15% in LVESV, measured 6 months after implant.
Conventional pacing vectors are the pacing vectors available both in the Quartet LV quadripolar lead and in the conventional bipolar leads.</description>
          <population>Patients with the 6-month follow-up completed, echocardiographic measurements available and programmed with a conventional pacing vector</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months after CRT implant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quadripolar Left Ventricular Lead (Quartet Lead)</title>
          <description>Patients implanted with a Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and the Quartet Left Ventricular (LV) quadripolar lead</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial or Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac arrest and death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Exacerbacion of Heart Failulre</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Exacerbacion of Heart Failulre and Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Myocardial infartion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malignant tumor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Calculous Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis due to amiodarone and statins treatment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Elevated Pacing Thresholds</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lead Dislodgement</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Phrenic Nerve/Diaphragmatic/Extracardiac stimulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding/Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sepsis and Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Inappropriate ATP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>phrenic nerve/diaphragmatic/extracardiac stimulation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Upgrade of the device to DDD by adding atrial lead</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Shiver and physical discomfort during implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bleeding/Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>carbon dioxide narcosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Coronary sinus dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nause and vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pain in the implant site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Javier Alzueta Rodríguez</name_or_title>
      <organization>Hospital Clinico Universitario Virgen de la Victoria</organization>
      <phone>951 03 20 00</phone>
      <email>jalzueta@telefonica.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

